Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 TAK-341 in multiple system atrophy
2022-000336-28Phase 2Active
- Sponsor
- Takeda
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing TAK-341 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 52 on UMSARS Part I. Started Jul 2022; status: active.
02
Drugs
MEDI1341
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2022-000336-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000336-28.